Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.80 USD

28.80
8,463,199

-0.29 (-1.00%)

Updated Sep 30, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use

by Zacks Equity Research

Merck's (MRK) oral antiviral molnupiravir secures the FDA-authorized emergency use tag in treating mild-to-moderate COVID-19 in adults for whom other FDA-approved COVID treatments are unsuitable.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves PFE & MRK's Oral Pills for COVID & Other Drugs

by Kinjel Shah

FDA approves Pfizer's (PFE) and Merck's (MRK) oral COVID antiviral pills and AstraZeneca's (AZN) asthma medicine, Tezspire (tezepelumab).

Sweta Jaiswal, FRM headshot

Pfizer ETFs to Rise on FDA's EUA for COVID-19 Oral Antiviral Pill

by Sweta Jaiswal, FRM

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the receipt of EUA for the antiviral COVID-19 pill.

Sweta Killa headshot

Santa Arrives! High Beta & Momentum ETFs to Tap the Rally

by Sweta Killa

With the Santa Claus rally, high-beta and high-momentum ETFs are expected to outperform in the seven-day period and are intriguing choices for a short spell.

Moderna (MRNA) Down as Pfizer Paxlovid EUA May Fuel Competition

by Zacks Equity Research

Moderna's (MRNA) COVID-19 vaccine may face stiffer competition following the FDA's emergency approval of an oral COVID-19 pill, Pfizer's Paxlovid, which may result in lower sales.

Pfizer (PFE) Gets FDA's Emergency Use Nod for COVID Pill

by Zacks Equity Research

Pfizer's (PFE) COVID-19 pill Paxlovid is the first oral antiviral medicine, which can be prescribed as an at-home treatment for mild-to-moderate COVID-19.

    Stock Market News for Dec 23, 2021

    by Zacks Equity Research

    Wall Street closed higher on Wednesday completing back-to-back rallies after three-days of Omicron-led decline.

    Novavax (NVAX) COVID-19 Booster Jab Effective Against Omicron

    by Zacks Equity Research

    Novavax's (NVAX) protein-based COVID vaccine shows a cross-reactivity response against the Omicron variant. It will also start clinical studies on an Omicron-specific vaccine in first-quarter 2022.

    Should You Invest in the Vanguard Health Care ETF (VHT)?

    by Zacks Equity Research

    Sector ETF report for VHT

    Pfizer (PFE) Stock Moves 1.02%: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Pfizer (PFE) closed at $59.55, marking a +1.02% move from the previous day.

    Mark Vickery headshot

    Markets Stay Up on Omicron News; Home Sales in Focus

    by Mark Vickery

    Today and yesterday, we've begun to see an influx of reports about Omicron blowing through populations rapidly but rather benignly.

    Novavax (NVAX) Commences COVID-19 Vaccine Booster Study

    by Zacks Equity Research

    Novavax (NVAX) initiates a phase III study to evaluate the booster dose of its COVID vaccine. WHO recommends administering the company's COVID vaccine booster to immunocompromised persons.

    Kinjel Shah headshot

    Will Lilly and Pfizer be Top Pharma Stocks Again in 2022?

    by Kinjel Shah

    Among the large drugmakers, stocks of Pfizer (PFE) and Eli Lilly (LLY) rose significantly in 2021 in response to their pipeline progress.

    Novavax (NVAX) COVID Vaccine Gets EU Nod, 2nd Listing by WHO

    by Zacks Equity Research

    Novavax (NVAX) secures approval for its COVID vaccine in the European Union. Following EU approval, WHO grants second emergency use listing to the company's COVID vaccine.

    Glaxo (GSK) Gets FDA Nod for HIV Preventive Injectable Drug

    by Zacks Equity Research

    Glaxo's (GSK) Apretude is the first and only long-acting injectable therapy approved for HIV prevention or PrEP.

    Moderna (MRNA) COVID-19 Booster Jab Effective Against Omicron

    by Zacks Equity Research

    Data from a pseudovirus study demonstrated that the authorized booster dose of Moderna's (MRNA) COVID-19 vaccine significantly increases neutralizing antibody levels against the Omicron variant.

    Sweta Killa headshot

    Biotech ETFs That Outperformed Last Week

    by Sweta Killa

    Biotech ETFs was the biggest gainer last week.

    Pfizer (PFE) to Test 3-Dose COVID-19 Vaccine Regimen in Kids

    by Zacks Equity Research

    Pfizer (PFE) and BioNTech (BNTX) to evaluate a third, 3 ug dose at least two months after the second dose of Comirnaty in children aged six months to five years for better protection against COVID-19.

    Tech-Stocks Under Pressure in the Pre-Markets

    by Zacks Equity Research

    Tech-Stocks Under Pressure in the Pre-Markets

    Mark Vickery headshot

    Markets Stay Red: Time for a Little Xmas Shopping?

    by Mark Vickery

    It's shaping up like a down week in the markets overall, despite a nice push higher following the most recent Fed policy adjustment mid-week.

    Pfizer (PFE) COVID Pill Paxlovid Gets CHMP Support in Europe

    by Zacks Equity Research

    The CHMP supports the use of Pfizer's (PFE) oral COVID-19 drug, Paxlovid, to treat high-risk patients even though it has not received conditional authorization from the European Commission.

    Indrajit Bandyopadhyay headshot

    U.S. CDC Recommends mRNA COVID-19 Vaccines Over J&J's Jab

    by Indrajit Bandyopadhyay

    The U.S. Centers for Disease Control and Prevention prefers the use of PFE, BNTX and MRNA's mRNA-based COVID-19 vaccines instead of J&J's adenovirus-based vaccine due to higher risks of side effects.

    Kinjel Shah headshot

    Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More

    by Kinjel Shah

    Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.

    Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod

    by Zacks Equity Research

    Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

    J&J's (JNJ) COVID-19 Booster Jab Gets CHMP Recommendation

    by Zacks Equity Research

    The CHMP recommends the use of the booster dose of J&J's (JNJ) COVID-19 vaccine in adults in Europe. The booster jab already enjoys authorization in the United States and from the WHO for use in adults.